An observational study in Chronic Obstructive Pulmonary Disease (COPD), Heart Failure and Cancer, sponsored by University Hospital, Geneva. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by University Hospital, Geneva · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland — 15 open to participants now, 20 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Switzerland.
Among the 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland, this one is the 19th largest by planned enrollment of the 22 observational ones that give a count, is one of 8 that started in 2025, is one of 22 observational ones, reaches primary completion later than 12 of the 19 other live ones, and was the 88th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →15 of the 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland are open now. Recruiting first, the newest first:
Matthias Wilhelm, MD · Sites in Switzerland
Ages 18+
University Hospital, Geneva · Sites in Switzerland
Ages 18+
Mona Lichtblau · Sites in Switzerland
Sanofi · Sites in Switzerland, United States, Argentina and 19 more countries
Ages 40–85
Medical University of Graz · Sites in Switzerland, Austria, United Kingdom
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 16 is below the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 74 across the 77 interventional studies, 128 across the 22 observational. Of the 71 that completed or were terminated, 20 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 99 have an industry lead sponsor. The 10 most frequent:
University Hospital, Geneva is the lead sponsor of 379 studies on the registry; 70 are open to participants now.
University Hospital, Geneva has 5 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
10 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07262229Institut et Haute Ecole de la Santé la SourceSelf-management Digital Intervention to Promote Physical Activity in People Living With COPD | 2026-11 |
| NCT02065921Prof. Dr. Jörg LeuppiSwiss Chronic Obstructive Pulmonary Disease (COPD) Management Cohort | 2026-12 |
| NCT07102823Medical University of GrazClinical Registry for the Characterization of the 'Pulmonary Vascular Phenotype' in Patients With Chronic Obstructive Pulmonary Disease | 2026-12-30 |
| NCT05163600University of ZurichThe Acute Cardiorespiratory Response to Blood-flow Restricted Versus Traditional Exercise Training Regimens (CaRe BFR) | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Dyspnea that persists despite optimal pathophysiological treatment is defined as persistent dyspnea.
Currently all brain functional magnetic resonance imaging (fMRI) studies conducted to evaluate breathlessness have done so using healthy volunteers or have concentrated on acute breathlessness. Little is known about chronic breathlessness patterns and their modulation by different triggers. Furthermore, it is currently assumed in the palliative care literature that patients suffering from different advanced and progressive diseases such as cancer, heart failure (HF) or chronic obstructive pulmonary disease (COPD) have the same triggers, perceptions and neurological pathways and thus require the same treatments/interventions (i.e. opioids as first line symptomatic pharmacologic treatment). However, it is now known that patients belonging to different disease groups do not necessarily benefit from opioids.
Aim of the study To assess the feasibility of identifying dyspnea patterns in different life-limiting conditions and to evaluate the effect of immersive virtual reality (IVR) on dyspnea using patient-reported-outcomes (PROMs).
Study procedure:
Patients with advanced chronic diseases such as cancer, COPD or HF suffering from dyspnea will undergo a brain fMRI in combination with an IVR intervention. The fMRI data will be reviewed to identify different patterns of dyspnea and the effect of IVR on dyspnea will be assessed through PROMs. Patients will be asked about the perceived burden of the study.
Dyspnea that persists despite optimal pathophysiologic treatment is defined as persistent dyspnea.
Breathlessness, also defined as dyspnea, is a frequent symptom in patients with advanced and progressive diseases such as cancer, chronic obstructive pulmonary disease (COPD) and advanced heart failure (HF). In affected patients, breathlessness causes substantial suffering and is a major contributor to decreased quality of life.
Despite increasingly controversial data on the effectiveness of opioids in advanced disease, they are often prescribed according to expert opinion. It can be hypothesized that breathlessness is conveyed by a variety of different pathophysiologies resulting in various patterns of the central nervous system (CNS) signalling, requiring more than a one-size-fits-all answer to pharmacologic interventions (i.e. opioids).
In recent years, the healthcare industry has seen the development of immersive virtual reality therapies (IVR), also called "digital therapeutics". Immersive virtual reality is an interactive computer simulation that allows a person to be completely immersed within a three-dimensional virtual environment so that it has a real feeling of being in the virtual world. IVR has been used during magnetic resonance imaging (MRI), to reduce stress and anxiety perceived by patients who suffer from claustrophobia.
Functional MRI (fMRI) measures brain activity by detecting changes associated with blood flow. Studies conducted to evaluate breathlessness have done so using healthy volunteers, focusing on acute breathlessness or in the context of pulmonary rehabilitation. Little is known about persistent breathlessness patterns and their modulation by different triggers.
Aim of the study:
It is possible that breathlessness is experienced and centrally processed in different ways between different patients, related to: i) the underlying disease, ii) the triggers for breathlessness episodes, iii) differences in patient-reported multidimensional assessment items (i.e. perceived severity vs discomfort vs effort). This study aims to assess whether different patterns of breathlessness can be identified by fMRI technology.
Hypothesis:
The investigators hypothesize that it is possible for patients suffering from persistent breathlessness associated with COPD, heart failure and incurable and life-limiting cancer to undergo an fMRI and associated study interventions.
Primary objective:
To determine the feasibility and acceptability of an observational monocentric study using fMRI and IVR in breathlessness patients with COPD, heart failure and cancer.
Secondary objective:
To identify different breathlessness fMRI signals in different diseases (COPD, heart failure, cancer) and identify different types of breathlessness patterns using fMRI, IVR, and clinical parameters (including patient-reported-outcome measures (PROMs)).
Project design The investigators plan to conduct an observational study that involves the use of an fMRI and IVR. A feasibility study design was chosen because the included patients need particular consideration and the feasibility of the procedure (fMRI) needs to be evaluated.
Total number of participants: four patients with HF, four patients with COPD, four patients with cancer, four healthy volunteers.
Participants will be recruited at the outpatient palliative care clinic of the HUG (single center) on the basis of a screening of medical records of patients and the preverification of the inclusion and exclusion criteria mentioned above.
The healthy controls will be recruited from a convenience sampling of known healthy volunteers meeting the above criteria, from a similar age group, under no hierarchical influence from any member of the research team.
Followed by the outpatient palliative care clinic of the Geneva University Hospitals, Switzerland (HUG)
Patient with a diagnosis of either HF stage NYHA III-IV or COPD with dyspnea on modified MRC scale grade 3-4 or oncological disease with either primary or secondary pulmonary location
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria for Healthy Volunteers (Control Group)
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients and healthy volunteers who will have a cerebral fMRI
Other: Cerebral fMRI · Other: Immersive virtual reality
Neuroimaging data will be collected using a 3T Siemens Prisma MRI scanner (Prisma; Siemens, Erlangen, Germany) equipped with a 64-channel head coil. Functional T2\*-weighted images will be acquired during the resting-state protocol. The sequences used will be gradient-echo planar imaging. Additionally, a single-band reference volume will be obtained prior to the functional acquisition, using the same parameters but without multiband (MB) acceleration, to assist in functional realignment and masking. A whole-brain T1-weighted multi-echo MPRAGE scan will also be performed with 1 mm isotropic resolution. three echo images were combined using the root-mean-square method.
In collaboration with HypnoVR (HypnoVR, Strasbourg, France), patients will subsequently be provided with a visual immersion in a virtual world along with a scripted hypnotic voice track. HypnoVR's solution is certified as a medical device and has been studied in various medical contexts. The program will be adapted to run on its own dedicated PC instead of a (non-MRI compatible) HMD. As described in this protocol, the PL and the patients can select from a predefined set of virtual environments and choose the preferred voice-over script.
Feasibility of the study
Composite outcomes: 1. Recruitment rate: proportion of eligible patients who consent to participate, calculated as the number of participants enrolled divided by the total number of eligible patients approached during the recruitment period. A recruitment rate ≥ 50% will be considered feasible. 2. Retention rate: proportion of enrolled participants who complete the planned intervention (fMRI, vital signs, and study-associated questionnaires). A retention rate ≥ 70% will be considered acceptable. If both thresholds are met (recruitment rate and retention rate), progression to a larger observational study will be considered.
Time frame: 18 months after the beginning of the study
Acceptability
The acceptability for the patients is based on the intervention's perceived burden, evaluated on a 5-point Likert scale (1 meaning no burden, 5 the maximum possible burden), recorded within 15 minutes after the intervention, with a cutoff ≤ 3, indicating that the study was moderately burdensome.
Time frame: 15 minutes after the procedure
Evolution of vital parameters
Saturation in oxygen (SpO2) (%) (minimum and maximum values)
Time frame: Before, during and 15 minutes after the fMRI
Evolution of vital parameters
Transcutaneous CO2 (ptCO2) (kPa) (minimum and maximum values)
Time frame: Pre and 15 minutes after the fMRI
Evolution of vital parameters
Respiratory rate over 1 minute (RR) (number/minute) (minimum and maximum values)
Time frame: Pre and 15 minutes after the fMRI
Evolution of dyspnea
Evolution of the dyspnea form before the fMRI, during and 15 min after the procedure on a numerical scale from 0-10.
Time frame: Before, during and 15 minutes after the fMRI
Evolution of vital parameters
Heart rate over 1 min (HR) (number/minute) (minimum and maximum values)
Time frame: Pre, during and 15 minutes after the fMRI
Claustrophobia questionnaire
Claustrophobia questionnaire. This questionnaire has 26 questions scored from 0 (not at all anxious) to 4 (extremely anxious). It has been used to evaluate claustrophobia and its two components (fear of suffocation and fear of restriction) in patients undergoing MRI.
Time frame: 15 minutes after the procedure
fMRI parameters
Percent signal change and latency of response in BOLD (blood-oxygen-level-dependent) signal change will be assessed in relevant brain regions, including the left precentral gyrus, left middle frontal gyrus, left insula, left amygdala, left hippocampus, medial orbitofrontal cortex, and brainstem regions.
Time frame: During the procedure
fMRI parameters
Functional connectivity of the left and right anterior insula with multiple regions (anterior cingulate cortex)
Time frame: During procedure
fMRI parameters
Activation map of the brain areas with significant activity as derived from the BOLD signal
Time frame: During procedure
fMRI parameters
Peak amplitude (maximum change in BOLD signal during the trigger) will be assessed in relevant brain regions, including the left precentral gyrus, left middle frontal gyrus, left insula, left amygdala, left hippocampus, medial orbitofrontal cortex, and brainstem regions.
Time frame: during procedure
fMRI parameters
Cluster size of contiguous voxels with a significant activation
Time frame: During procedure
fMRI parameters
Measures of coupling between resting-state fMRI and respiration oscillations will be assessed in relevant brain regions, including the left precentral gyrus, left middle frontal gyrus, left insula, left amygdala, left hippocampus, medial orbitofrontal cortex, and brainstem regions, based on directed transfer analysis.
Time frame: During procedure
fMRI parameters
Perfusion MRI outcomes based on dynamic susceptibility contrast MR perfusion measurements: relative cerebral blood flow (rCBF) maps that allow determining rCBF in the left and right anterior insula
Time frame: During procedure
Plan to share: Undecided
Started Aug 2025 (actual). Primary completion is estimated for Mar 2027, 18 months after the start.
Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 18 months is below that.
Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →